Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Change in Receivables (2018 - 2024)

Serina Therapeutics (SER) has disclosed Change in Receivables for 7 consecutive years, with -$163000.0 as the latest value for Q1 2024.

  • Quarterly Change in Receivables fell 89.53% to -$163000.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $172000.0 through Jun 2024, up 159.31% year-over-year, with the annual reading at $53000.0 for FY2023, 352.38% up from the prior year.
  • Change in Receivables hit -$163000.0 in Q1 2024 for Serina Therapeutics, down from -$10000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $345000.0 in Q3 2023 to a low of -$196000.0 in Q2 2023.
  • Historically, Change in Receivables has averaged -$13470.6 across 5 years, with a median of -$11000.0 in 2020.
  • Biggest five-year swings in Change in Receivables: tumbled 3650.0% in 2020 and later skyrocketed 3236.36% in 2023.
  • Year by year, Change in Receivables stood at $124000.0 in 2020, then crashed by 99.19% to $1000.0 in 2021, then surged by 200.0% to $3000.0 in 2022, then plummeted by 433.33% to -$10000.0 in 2023, then plummeted by 1530.0% to -$163000.0 in 2024.
  • Business Quant data shows Change in Receivables for SER at -$163000.0 in Q1 2024, -$10000.0 in Q4 2023, and $345000.0 in Q3 2023.